International Cannabinoid Research Society’s (or ICRS) was founded in 1992. Since then more than 500 international members meet each year to share their ideas on studies of cannabinoids and its influence on the human body on different levels: biochemical, chemical and psychological, right up to recreational weed abuse problems. In the end of June it was the 25th forum conducted every year. The society is laboring on cannabis for new information, while legalization of marijuana for recreational use gaining speed. More than 70 constituents of marijuana’s are cannabinoids known to researchers, each with unique pharmacological properties.
The professionals provided new scientific proofs of marijuana’s healing properties that seem to be very promising for humans. Thanks to that, in the nearest future we may find remedies for staying slim and eat as much as we wish, or create a new medicine for Schizophrenia.
Metabolism is one of the key processes in the human body. Dr. George Kunos and his group shared new information on dual-target CB1 receptors antagonist which also can affect other receptors responsible for liver fibrosis and inflammation. Liver disease can be caused by infection, alcohol, viruses, obesity. The researchers have synthesized a set of ingredients that inhibit peripheral CB1 receptors in liver, fat and muscle, without much impact on the brain. It means that they can stabilize blood sugar, control fat loss and obesity. It gives hope that conditions like abdominal fat, metabolic syndrome and carbohydrate intolerance may be treated with natural components.
Researchers from Texas A&M and UConn talked about new ways of studying and classifying new components in marijuana which bind to CB1r in a different way compared to THC. Such ingredients are less psychoactive than THC, but in the same time, more effective in performing anti-inflammatory and anti-pain (and other similar) functions. This kind of studies are very important, they can open the doors to wider application of marijuana by eliminating adverse “high effect”, which is the main reason for its prohibition by the government.
The latest study of J. Renard, J. Loureiro from the University of Western Ontario states that CBD can give us hope to treat Schizophrenia with natural components. Schizophrenia is a psychiatric disorder currently treated with a combination of anti psychotic drugs that affect dopamine (DA) receptors, accompanied by adverse side effects. The research group has found a new pathway on molecular level through which CBD reduces schizophrenia-like neuropsychopathology in mice.
C.E. Herron from University College of Dublin, Ireland presented the results of the CBD study aimed at neurodegenerative disorders, including Alzheimer’s disease (AD). Having showed that CBD provides protection against the neuro-toxic effects of beta amyloid peptide (Aβ) in cultured cells, thus reducing the attenuation of hippocampal (the part in the brain responsible for memory) long-term potentiation in models of Alzheimer’s disease, the study proved CBD to be neuro-protective and may be a useful therapeutic substance for the treatment of AD.
80% of cancer patients have to endure side effects as weight loss and fatigue. D.I. Brierley’s research group from University of Reading, Berkshire, UK shared information on another cannabis constituent, CBG (cannabigerol). Performed on rats treated with cisplatin chemotherapy, this experiment showed, that taken orally, CBG not only stopped weight loss, but increased food intake. Apart from that, types of muscles IIa and IIx were well protected and thus not harmed. That shows again that cancer-induced cachexia may be partially treated with CBG.
Marijuana is the most widely consumed illegal drug on our planet, it requires more studies to understand neuropsychopharmacological mechanisms that underlie the diffuse effects of cannabis in the brain.